知镜 Cognispect · 医学文献与研究工作台

Ventricular tachycardia substrate mapping with cardiac computed tomography and cardiac magnetic resonance imaging: Head-to-head comparison of two clinically available postprocessing platforms.

Laan D, Hopman LHGA, Figueras I Ventura RM, Soré B, Allaart CP, Kemme MJB, Götte MJW, Postema PG, Bhagirath P.
Heart rhythm · 2025-09-19 · PMID 40976541

文献摘要

Background Advanced postprocessing of late gadolinium enhancement cardiac magnetic resonance (CMR) and computed tomography (CCT) imaging increasingly guides ventricular tachycardia ablation. However, a direct comparison between 2 widely adopted platforms, ADAS 3D LV (Adas3D Medical) and inHEART (IHU Liryc/Inria), is lacking. Objective This study aimed to compare CMR- and CCT-derived ventricular substrate models generated by ADAS 3D and inHEART in patients with ischemic and nonischemic cardiomyopathy undergoing ventricular tachycardia ablation. Methods Patients who underwent both CCT and late gadolinium enhancement CMR before ablation were retrospectively included. ADAS 3D models were generated on-site, whereas inHEART models were processed remotely. Substrate models were evaluated using a custom scoring system incorporating quantitative (scar mass, transmurality) and qualitative parameters (wall thickness, scar delineation, and conduction corridors). Electroanatomic maps (EAMs) assessed correspondence between low-voltage and ablation regions, with imaging-defined corridors. Results 16 patients (n = 8 ischemic, n = 8 nonischemic) were analyzed; 12 had detailed EAM data. Scar core and border zone measurements were comparable between platforms in both subgroups (all P > .05). ADAS 3D showed slightly higher visualization scores, particularly in nonischemic cardiomyopathy, although differences were not statistically significant. Spatial concordance between imaging-derived scar and EAM-defined ablation areas was good to excellent in 10 of 12 cases. Conclusion ADAS 3D and inHEART demonstrated high concordance in scar quantification and substrate characterization, with comparable performance across cardiomyopathy types. Given their complementary strengths, platform choice should be guided by procedural goals, imaging availability, operator experience, and institutional context, as each system offers distinct advantages. Prospective studies are needed to evaluate the impact on procedural success and long-term outcomes.

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。